<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Micafungin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Micafungin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Micafungin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10141" href="/d/html/10141.html" rel="external">see "Micafungin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11353" href="/d/html/11353.html" rel="external">see "Micafungin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F196257"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mycamine</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867554"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Mycamine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1761796"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antifungal Agent, Echinocandin</span>;</li>
<li>
<span class="list-set-name">Antifungal Agent, Systemic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462507"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7a487bb-a32b-410e-85bb-cea78c6c85cb">Candidiasis, systemic, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, systemic, treatment:</b> IV: 10 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19890251','lexi-content-ref-Bradley.1','lexi-content-ref-23137136','lexi-content-ref-HHS.3','lexi-content-ref-29762386','lexi-content-ref-29744900','lexi-content-ref-AAP.1','lexi-content-ref-29601453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19890251','lexi-content-ref-Bradley.1','lexi-content-ref-23137136','lexi-content-ref-HHS.3','lexi-content-ref-29762386','lexi-content-ref-29744900','lexi-content-ref-AAP.1','lexi-content-ref-29601453'])">Ref</a></span>); doses as high as 15 mg/kg/dose have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27697761','lexi-content-ref-19319022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27697761','lexi-content-ref-19319022'])">Ref</a></span>). Duration of therapy should be individualized based on clinical response and presence of deep foci; treat for a minimum of 14 days from the first negative blood culture for candidemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137136','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137136','lexi-content-ref-26679628'])">Ref</a></span>). <b>Note:</b> Manufacturer labeling recommends 4 mg/kg/dose once daily in patients without CNS or ocular involvement; however, a pharmacokinetic model in patients 1 to 7 kg suggested that doses of 3 to 4 mg/kg/day in neonates and young infants would result in only 40.5% to 43.3% of patients achieving exposure similar to adults receiving 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27697761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27697761'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F21664241"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7beae89c-e2c7-4a13-a271-1d760b3b7cc4">Aspergillosis, invasive; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive; treatment (salvage therapy):</b> Infants, Children, and Adolescents: Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In infants, initial doses at the higher end of the dosage range may be necessary due to pharmacokinetic differences (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>). Treatment duration should be individualized based on patient-specific factors including site of infection, immunosuppression, and response to therapy; minimum duration is 6 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">≤40 kg: IV: 2 to 3 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-27365388'])">Ref</a></span>); higher doses of 4 to 6 mg/kg/dose once daily have also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24730676','lexi-content-ref-16915374','lexi-content-ref-23743960','lexi-content-ref-12621247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24730676','lexi-content-ref-16915374','lexi-content-ref-23743960','lexi-content-ref-12621247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;40 kg: IV: 100 mg/dose once daily; may increase to 150 mg/dose if clinically indicated; maximum daily dose: 150 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-21905789','lexi-content-ref-27365388','lexi-content-ref-28317305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-21905789','lexi-content-ref-27365388','lexi-content-ref-28317305'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2bd63e09-635f-4b3b-ac73-b3f4a49de4b5">Candidiasis, esophageal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, esophageal</b> (alternative agent in patients who cannot tolerate oral therapy):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-HIV-exposed/-infected</i>: Infants ≥4 months, Children, and Adolescents: <b>Note:</b> IDSA guidelines recommend 14 to 21 days of treatment for esophageal candidiasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≤30 kg: IV: 3 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;30 kg: IV: 2.5 mg/kg/dose once daily; maximum dose: 150 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected</i> (HHS [OI adult 2019]; HHS [OI pediatric 2019]): <b>Note:</b> Treatment is recommended for 14 to 21 days for esophageal candidiasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-HHS.3'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;15 kg: IV: 5 to 7 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 8 years and ≤40 kg: IV: 3 to 4 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥9 years:</p>
<p style="text-indent:-2em;margin-left:8em;">≤40 kg: IV: 2 to 3 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;40 kg: IV: 100 mg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV: 150 mg/dose once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b20d0a7-708b-40d9-b2f6-b40ee698abff">Candidiasis, systemic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, systemic (including candidemia and invasive candidiasis):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Duration of therapy should be individualized (based on deep-tissue foci, clinical response, etc); candidemia should be treated for a minimum of 14 days from the first negative blood culture and resolution of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137136','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137136','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;4 months: IV: 10 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29596222','lexi-content-ref-23137136','lexi-content-ref-29762386','lexi-content-ref-29744900','lexi-content-ref-29601453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29596222','lexi-content-ref-23137136','lexi-content-ref-29762386','lexi-content-ref-29744900','lexi-content-ref-29601453'])">Ref</a></span>); doses as high as 15 mg/kg/dose have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27697761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27697761'])">Ref</a></span>). <b>Note:</b> Manufacturer labeling recommends 4 mg/kg/dose once daily in patients without CNS or ocular involvement; however, a pharmacokinetic model in patients weighing 1 to 7 kg suggested that doses of 3 to 4 mg/kg/day in neonates and young infants would only result in 40.5% to 43.3% of patients achieving exposure similar to adults receiving 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27697761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27697761'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months, Children, and Adolescents: IV: Initial: 2 mg/kg/dose once daily; usual maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-Mycamine.3','lexi-content-ref-18679151','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-Mycamine.3','lexi-content-ref-18679151','lexi-content-ref-manu.1'])">Ref</a></span>); may increase to 4 mg/kg/dose if clinical condition does not improve or mycologic persistence occurs at lower doses; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mycamine.3','lexi-content-ref-18679151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mycamine.3','lexi-content-ref-18679151'])">Ref</a></span>). Manufacturer labeling recommends 2 mg/kg/dose once daily in patients without CNS or ocular involvement; however, a pharmacokinetic model indicates that doses of 3 to 4 mg/kg/day may be necessary to achieve AUC:MIC targets against <i>Candida albicans</i> in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26602452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26602452'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d816b71-c051-435e-8794-a3f47454a7ea">Empiric antifungal therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Empiric antifungal therapy (neutropenic fever): </b>Infants ≥4 months, Children, and Adolescents: IV: 2 to 3 mg/kg/dose once daily; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388','lexi-content-ref-23743960','lexi-content-ref-26880109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388','lexi-content-ref-23743960','lexi-content-ref-26880109'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1dfe58f5-f783-4861-ba32-d1d722f27466">Fungal infection, prophylaxis in hematopoietic stem cell transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fungal infection, prophylaxis in hematopoietic stem cell transplant (HSCT) recipients:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;4 months: Limited data available: IV: 2 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mycamine.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mycamine.3'])">Ref</a></span>); dose based on pharmacokinetic exposure similar to adults receiving 50 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months, Children, and Adolescents: IV: 1 mg/kg/dose once daily; maximum dose: 50 mg/dose; doses as high as 3 mg/kg/day have been used in trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19533659','lexi-content-ref-15546073','lexi-content-ref-24567233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19533659','lexi-content-ref-15546073','lexi-content-ref-24567233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Alternate day dosing:</i> Very limited data available: Infants ≥7 months and Children ≤10 years: IV: 3 mg/kg/dose every 48 hours; dosing based on a small pharmacokinetic modeling study in which a total of 15 patients (age: 0.6 months to 10 years) undergoing HSCT received a single dose of 3 mg/kg of micafungin; modeled exposures with 3 mg/kg/dose every 48 hours were similar to those achieved in previous studies evaluating 1 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20546908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20546908'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130282"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; not dialyzable, supplemental dosing is not required following hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51130283"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doa drugH1Div" id="F196258"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10141" href="/d/html/10141.html" rel="external">see "Micafungin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88c58fcb-77ef-4148-803b-f83c6e2aa28b">Aspergillosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive (including disseminated and extrapulmonary) (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for salvage therapy, typically as part of an appropriate combination regimen. Monotherapy is further reserved for patients who are intolerant of or refractory to azoles and polyenes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388','lexi-content-ref-Patterson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388','lexi-content-ref-Patterson.1'])">Ref</a></span>); for patients with severe or progressive infection, some experts use as initial therapy in combination with voriconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16678903','lexi-content-ref-Patterson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16678903','lexi-content-ref-Patterson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 to 150 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388','lexi-content-ref-18983417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388','lexi-content-ref-18983417'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: When given as monotherapy, the minimum duration is 6 to 12 weeks depending on degree/duration of immunosuppression, disease site, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>); immunosuppressed patients may require more prolonged treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-Patterson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-Patterson.1'])">Ref</a></span>). When given as part of a combination regimen, the optimal duration is uncertain. Some experts have given an echinocandin for ~2 weeks in combination with voriconazole before step-down to voriconazole monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25599346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25599346'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Candidemia (neutropenic and nonneutropenic patients), including disseminated candidiasis:</i> IV:</b> 100 mg once daily. Total duration (including oral step-down therapy) is ≥14 days after first negative blood culture and continues until signs/symptoms of candidemia and neutropenia, if present, have resolved; metastatic complications warrant a longer duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-17806055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-17806055'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Cardiac device infection (including implantable cardiac defibrillator, pacemaker, ventricular assist device) (off-label use)</i>
<i>:</i> IV:</b> 150 mg once daily; step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥4 weeks after device removal for isolated generator pocket infection and ≥6 weeks after device removal for wire infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic disseminated (hepatosplenic) (off-label use):</i></b>
<b>IV:</b> 100 mg once daily for several weeks, followed by oral azole step-down therapy until lesion resolution and through periods of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Empiric therapy, suspected invasive candidiasis (nonneutropenic ICU patients) (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Antifungal therapy is not routinely warranted for initial management of nonneutropenic patients with sepsis. Consider use for critically ill patients with unexplained fever or unexplained hypotension despite broad-spectrum antimicrobial therapy and risk factors for invasive candidiasis (eg, indwelling venous catheter, hemodialysis, trauma or burns, recent surgery, parenteral nutrition) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-34599691','lexi-content-ref-Vazquez.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-34599691','lexi-content-ref-Vazquez.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 100 mg once daily. For those who improve, continue empiric antifungal therapy for 2 weeks; consider discontinuing after 4 to 5 days in patients with no evidence of invasive candidiasis and no clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Endocarditis, native or prosthetic valve (off-label use):</i></b>
<b>IV:</b> 150 mg once daily; step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscesses, other complications, or a nonsurgical approach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Esophageal, refractory disease (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve for fluconazole-refractory disease in patients who require IV therapy (eg, severe disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 150 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-15801925','lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-15801925','lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-Kauffman.1'])">Ref</a></span>). Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Intra-abdominal infection (eg, peritonitis, abdominal abscess):</i> IV:</b> 100 mg once daily. Total duration (including oral step-down therapy) is ≥14 days and continues until source control and clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-17806055','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-17806055','lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Oropharyngeal, refractory disease (alternative agent) (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve for fluconazole-refractory disease in patients who require IV therapy (eg, severe disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 100 mg once daily. Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Kauffman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Kauffman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Osteoarticular infection (osteomyelitis or septic arthritis) (off-label use):</i></b>
<b>IV: </b>100 mg once daily for ≥2 weeks; total duration of therapy (including oral step-down therapy) is 6 to 12 months for osteomyelitis and ≥6 weeks for septic arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Vazquez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Vazquez.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Thrombophlebitis, suppurative (off-label use):</i></b>
<b>IV:</b> 150 mg once daily; continue antifungal therapy until catheter removed and thrombus resolved, and for ≥2 weeks after candidemia (if present) has cleared (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b4cc183-e762-44d3-9d4d-6ff926a219f3">Neutropenic fever, empiric antifungal therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empiric antifungal therapy (alternative agent) (off-label use): </b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended for patients with persistent or recurrent fever after ≥4 days of antimicrobial therapy when the duration of neutropenia is expected to exceed 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-27365388'])">Ref</a></span>). Some experts reserve for patients without suspicion of mold infection (eg, pulmonary nodules) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388','lexi-content-ref-17202726','lexi-content-ref-16595990']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388','lexi-content-ref-17202726','lexi-content-ref-16595990'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c68abc8a-b79f-4368-a4bf-6161f16dfcf1">Prophylaxis against invasive fungal infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prophylaxis against invasive fungal infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hematologic malignancy or hematopoietic cell transplant (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Some experts reserve for patients at low risk for mold infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30179565','lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30179565','lexi-content-ref-Wingard.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 50 to 100 mg once daily. Duration is at least until resolution of neutropenia and varies based on degree and duration of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30179565','lexi-content-ref-29746955','lexi-content-ref-22469884','lexi-content-ref-21258094','lexi-content-ref-27365388','lexi-content-ref-15546073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30179565','lexi-content-ref-29746955','lexi-content-ref-22469884','lexi-content-ref-21258094','lexi-content-ref-27365388','lexi-content-ref-15546073'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Solid organ transplant (alternative agent) </i></b>
<i>(<b>off-label use):</b></i>
<b>IV:</b> 100 mg once daily; duration varies based on patient risk factors and transplant center protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-30900296','lexi-content-ref-Fishman.1','lexi-content-ref-27365388','lexi-content-ref-25520332','lexi-content-ref-23842191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-30900296','lexi-content-ref-Fishman.1','lexi-content-ref-27365388','lexi-content-ref-25520332','lexi-content-ref-23842191'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990667"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16172179','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16172179','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Poorly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17473532','lexi-content-ref-24505092','lexi-content-ref-26096213','lexi-content-ref-30633087','lexi-content-ref-28584142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17473532','lexi-content-ref-24505092','lexi-content-ref-26096213','lexi-content-ref-30633087','lexi-content-ref-28584142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987908"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F196235"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Phlebitis (19%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Diarrhea (7% to 11%), vomiting (7% to 18%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia (infants, children, and adolescents: 18%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Abnormal hepatic function tests (4%; infants, children, and adolescents: &lt;15%), hyperbilirubinemia (infants, children, and adolescents: &lt;15%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Renal failure syndrome (infants, children, and adolescents: &lt;15%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (9% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Atrial fibrillation (adults: 3%), tachycardia (infants, children, and adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Abnormal aspartate transaminase (3%), hyperkalemia (adults: 5%), hypoglycemia (adults: 6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distention (infants, children, and adolescents: 2%), abdominal pain (infants, children, and adolescents: 4%), nausea (7% to 10%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Neutropenia (infants, children, and adolescents: 5%), thrombocytopenia (infants, children, and adolescents: 9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased serum alkaline phosphatase (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache (adults: 9%)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Candidiasis prophylaxis in hematopoietic stem cell transplantation</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Tachycardia (16% to 26%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Pruritus (infants, children, and adolescents: 33%), skin rash (25% to 30%), urticaria (&lt;5%; infants, children, and adolescents: 19%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distention (infants, children, and adolescents: 19%), abdominal pain (26% to 35%), diarrhea (77%; infants, children, and adolescents: 51%), nausea (70% to 71%), vomiting (65% to 66%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Decreased urine output (infants, children, and adolescents: 23%), hematuria (infants, children, and adolescents: 23%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia (infants, children, and adolescents: 51%), febrile neutropenia (infants, children, and adolescents: 16%), neutropenia (75% to 77%), thrombocytopenia (72% to 75%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Abnormal hepatic function tests (infants, children, and adolescents: &lt;15%), hyperbilirubinemia (infants, children, and adolescents: &lt;15%), increased serum alanine aminotransferase (16%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Anxiety (22% to 23%), headache (adults: 44%), insomnia (adults: 37%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Renal failure syndrome (infants, children, and adolescents: &lt;15%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (infants, children, and adolescents: 61%), infusion-related reaction (infants, children, and adolescents: 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Acute myocardial infarction (adults: &lt;5%), pericardial effusion (adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hypernatremia (&lt;5%), hypokalemia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood (adults: &lt;5%), pancytopenia (adults: &lt;5%), thrombotic thrombocytopenic purpura (adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Hepatic failure (adults: &lt;5%), hepatic injury (adults: &lt;5%), hepatomegaly (adults: &lt;5%), jaundice (adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Anaphylaxis (adults: &lt;5%), hypersensitivity reaction (adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Infusion site reaction (adults: &lt;5%), venous thrombosis at injection site (adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Encephalopathy (adults: &lt;5%), delirium (adults: &lt;5%), intracranial hemorrhage (adults: &lt;5%), seizure (adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Epistaxis (infants, children, and adolescents: 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Shock, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Facial swelling, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation, hemolysis, hemolytic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, nonimmune anaphylaxis, severe hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site phlebitis, thrombophlebitis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, renal insufficiency</p></div>
<div class="block coi drugH1Div" id="F196246"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to micafungin, other echinocandins, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F196233"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia/hemoglobinuria: Hemolytic anemia and hemoglobinuria have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: New-onset or worsening hepatic impairment, including hepatitis and hepatic failure, has been reported. Monitor closely and evaluate appropriateness of continued use in patients who develop abnormal liver function tests during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe anaphylactic reactions, including shock, have been reported. Infusion reactions (eg, rash, pruritus, facial swelling, vasodilatation) have also been reported. Infusion should be discontinued for serious hypersensitivity reactions (eg, anaphylaxis). The infusion rate may be slowed for possible histamine-mediated infusion reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection-site reactions: Injection-site reactions (eg, phlebitis, thrombophlebitis) have been reported; more frequent with peripheral administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Increased BUN, serum creatinine, renal dysfunction, and/or acute renal failure has been reported; use with caution in patients that develop worsening renal function during treatment; monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Data suggest that micafungin clearance increases as a function of weight; higher doses may be necessary in patients with obesity (Hall 2011). There are limited data to define the optimal dose in this population (Maseda 2018; Pasipanodya 2015; Wasmann 2019).</p></div>
<div class="block foc drugH1Div" id="F196241"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mycamine: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mycamine: 50 mg (1 ea [DSC]) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mycamine: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mycamine: 100 mg (1 ea [DSC]) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 100 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F3884043"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323399"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Micafungin Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $31.20 - $112.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $57.60 - $224.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Mycamine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $112.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $224.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867555"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mycamine: 50 mg (1 ea); 100 mg (1 ea) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 100 mg (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52613326"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: In pediatric patients, final concentrations  &gt;1.5 mg/mL should be administered via a central line to minimize risk of infusion reactions. Prior to administration, flush line with NS. Infuse over 1 hour; more rapid infusions may result in a higher incidence of histamine-mediated reactions. Do not coinfuse with other medications since precipitation may occur. </p></div>
<div class="block adm drugH1Div" id="F196243"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV use only; infuse over 1 hour; may reduce infusion rate for infusion reaction (eg, rash, pruritus, facial swelling, vasodilatation). Flush line with NS prior to administration.</p></div>
<div class="block sts drugH1Div" id="F196252"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C  to 30°C (59°F to 86°F). Reconstituted and diluted solutions in D5W or NS are stable for 24 hours at room temperature. Protect infusion solution from light (it is not necessary to protect the drip chamber or tubing from light).</p></div>
<div class="block usep drugH1Div" id="F53567841"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of candidemia, acute disseminated candidiasis, <i>Candida </i>peritonitis and abscess <b>without </b>meningoencephalitis and/or ocular dissemination (FDA approved in ages &lt;4 months); treatment of candidemia, acute disseminated candidiasis, <i>Candida</i> peritonitis and abscess (FDA approved in ages ≥4 months and adults); treatment of esophageal candidiasis (FDA approved in ages ≥4 months and adults); prophylaxis of <i>Candida</i> infections in patients undergoing hematopoietic stem cell transplant (FDA approved in ages ≥4 months and adults); has also been used for treatment of invasive <i>Aspergillosis</i>.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Micafungin is ineffective against cryptococcosis, fusariosis, and zygomycosis.</p></div>
<div class="block cyt drugH1Div" id="F747105"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F747104"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus Products: Micafungin may increase the serum concentration of Sirolimus Products. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F196248"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than micafungin are preferred for the treatment of candidiasis in pregnancy (IDSA [Pappas 2016]).</p></div>
<div class="block mopp drugH1Div" id="F53567838"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of infusion reaction (histamine-mediated symptoms) including rash, pruritus, facial swelling, and vasodilation. AST, ALT, bilirubin, SCr, BUN, serum potassium, and CBC (baseline and periodically during therapy; increase monitoring in patients who develop abnormalities) (Arrieta 2011).</p></div>
<div class="block pha drugH1Div" id="F196232"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Concentration-dependent inhibition of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, an essential polysaccharide comprising 30% to 60% of <i>Candida</i> cell walls (absent in mammalian cells); decreased glucan content leads to osmotic instability and cellular lysis</p></div>
<div class="block phk drugH1Div" id="F196245"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Poor.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes into lung, liver, and spleen; minimally to CNS and eyes (Caudle 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm infants: Reported data highly variable; possibly dependent on GA/weight and PNA: V<sub>dss</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 0 to 1 day, weight &lt;1,500 g: 0.76 ± 0.28 L/kg (Kawada 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;4 days, weight &lt;2,500 g: 1.515 ± 0.516 L/kg (Smith 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;3 weeks, weight ≥1,000 g: 0.43 ± 0.11 L/kg (range: 0.28 to 0.66 L/kg) (Heresi 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and infants &lt;4 months: Median 0.35 L/kg (range: 0.225 to 0.482 L/kg) (Leroux 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months and Children &lt;2 years: 0.319 ± 0.0615 L/kg (range: 0.24 to 0.45 L/kg) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 8 years: V<sub>dss</sub>: 0.35 ± 0.18 L/kg (Seibel 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 years and Adolescents ≤17 years: V<sub>dss</sub>: 0.28 ± 0.09 L/kg (Seibel 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: V<sub>d</sub>: 0.39 ± 0.11 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Neonates: 96.7% (Yanni 2011); Adults: &gt;99% to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to M-1, catechol form by arylsulfatase; further metabolized to M-2, methoxy form by catechol-O-methyltransferase; hydroxylation to M-5 by CYP3A.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm infants:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;1 week: 6.7 ± 2.2 hours (Kawada 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;3 weeks: Mean 8.3 hours (range: 5.6 to 11 hours) (Heresi 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Term and preterm infants &lt;4 months: Mean range: 11 to 13.6 hours (Benjamin 2010; Leroux 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months and Children &lt;2 years: 11.5 ± 2.17 hours (range: 7.9 to 16 hours) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: 11.1 ± 1.32 hours (range: 8.9 to 13.8 hours) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: 14.7 ± 6.98 hours (range: 9.8 to 28.4 hours) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;margin-right:2em;">Children ≥12 years and Adolescents ≤16 years: 13.1 ± 1.68 hours (range: 10.5 to 16.2 hours) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Healthy Adults: 11 to 21 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults receiving bone marrow or peripheral stem-cell transplantation: 10.7 to 13.5 hours (Carver 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months, Children, and Adolescents ≤16 years: 0.9 to 2 hours (Albano 2015; Benjamin 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces (71%); urine (&lt;1%, unchanged [Hebert 2005]).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm infants:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 0 to 1 day, weight &lt;1,500 g: 1.48 ± 0.78 mL/minute/kg (Kawada 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;4 days, weight &lt;2,500 g: 0.575 ± 0.196 mL/minute/kg (Smith 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;3 weeks, weight ≥1,000 g: 0.648 ± 0.2 mL/minute (Heresi 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Term and preterm infants &lt;4 months: 0.5 ± 0.2 mL/minute/kg (range: 0.2 to 0.8 mL/minute/kg) (Benjamin 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months and Children &lt;2 years: 0.328 ± 0.046 mL/minute/kg (range: 0.243 to 0.402 mL/minute/kg) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: 0.34 ± 0.058 mL/minute/kg (range: 0.237 to 0.4 mL/minute/kg) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: 0.22 ± 0.039 mL/minute/kg (range: 0.155 to 0.267 mL/minute/kg) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤16 years: 0.217 ± 0.037 mL/minute/kg (range: 0.17 to 0.278 mL/minute/kg) (Albano 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~0.3 mL/minute/kg.</p></div>
<div class="block phksp drugH1Div" id="F51159556"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Moderate impairment (Child-Pugh class B): AUC and C<sub>max </sub>reduced ~22% compared to normal hepatic function. Severe impairment (Child-Pugh class C): AUC and C<sub>max</sub> of parent drug reduced ~30% compared to normal hepatic function (no dose adjustment required).</p>
<p style="text-indent:-2em;margin-left:2em;">Obesity: Data suggest that micafungin clearance increases as a function of weight (Hall 2011).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038681"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Micafungin hikma | Micafungin ratiopharm | Mycamine</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Micafungin teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Micafungin olikla | Micafungin teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Micafungin inresa | Micafungin mylan | Micafungin Pharmore | Mycamine</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Micafungina accord | Micafungina sala | Micafungina Sandoz | Micafungina Teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Micafungine mylan | Micafungine ohre pharma | Mycamine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Micafungin | Micafungin teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Micafungin pharmacenter | Micafungin teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">B cagin | Ibimica | Ivfungin | Micafung | Micalan | Micanfa | Micedge | Mycamine | Mykes</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Micafungina hikma | Micafungina Teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Funguard</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Micafungine hikma | Micafungine mylan | Micafungine teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Micafungin accord | Micafungin teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Micafungin | Mycamine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Micafungina accord | Micafungina hikma | Micafungina Teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Micafungin-nativ | Micamin | Mycamine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Micafungin bioglan | Micafungin mylan | Mikafungin teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mikafungin teva | Mycamine</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Micafungin olikla | Mycamine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mifundex | Mikafungus | Myacit | Mycamine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Micamin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mycamine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25072363">
<a name="25072363"></a>Albano E, Azie N, Roy M, Townsend R, Arrieta A. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation. <i>J Pediatr Hematol Oncol</i>. 2015;37(1):e45-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/25072363/pubmed" id="25072363" target="_blank">25072363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21378595">
<a name="21378595"></a>Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. <i>Pediatr Infect Dis J</i>. 2011;30(6):e97-e102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/21378595/pubmed" id="21378595" target="_blank">21378595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18433348">
<a name="18433348"></a>Ashouri N, Singh J, Arrieta A. Micafungin in pediatrics: when one size does not fit all. <i>Expert Opin Drug Metab Toxicol</i>. 2008;4(4):463-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/18433348/pubmed" id="18433348" target="_blank">18433348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31155770">
<a name="31155770"></a>Aslam S, Rotstein C; AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13623. doi:10.1111/ctr.13623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/31155770/pubmed" id="31155770" target="_blank">31155770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27697761">
<a name="27697761"></a>Auriti C, Falcone M, Ronchetti MP, et al. High-dose micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. <i>Antimicrob Agents Chemother</i>. 2016;60(12):7333-7339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/27697761/pubmed" id="27697761" target="_blank">27697761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23958810">
<a name="23958810"></a>Benjamin DK Jr, Deville JG, Azie N, et al. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. <i>Pediatr Infect Dis J</i>. 2013;32(11):e419-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/23958810/pubmed" id="23958810" target="_blank">23958810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29596222">
<a name="29596222"></a>Benjamin DK Jr, Kaufman DA, Hope WW, et al. A phase 3 study of micafungin versus amphotericin B deoxycholate in infants with invasive candidiasis [published correction appears in <i>Pediatr Infect Dis J</i>. 2018;37(11):1198]. <i>Pediatr Infect Dis J</i>. 2018;37(10):992-998.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/29596222/pubmed" id="29596222" target="_blank">29596222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19890251">
<a name="19890251"></a>Benjamin DK Jr, Smith PB, Arrieta A, et al, "Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants," <i>Clin Pharmacol Ther</i>, 2010, 87(1):93-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19890251/pubmed" id="19890251" target="_blank">19890251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>Candidiasis (Mucocutaneous). In: US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated May 26, 2020. Accessed June 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15340133">
<a name="15340133"></a>Carver PL, “Micafungin,” <i>Ann Pharmacother</i>, 2004, 38(10):1707-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/15340133/pubmed" id="15340133" target="_blank">15340133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22190252">
<a name="22190252"></a>Caudle KE, Inger AG, Butler DR, et al. Echinocandin use in the neonatal intensive care unit. <i>Ann Pharmacother</i>. 2012;46:108-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/22190252/pubmed" id="22190252" target="_blank">22190252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15472817">
<a name="15472817"></a>de Wet N, Llanos-Cuentas A, Suleiman J, et al, “A Randomized, Double-Blind, Parallel-Group, Dose-Response Study of Micafungin Compared With Fluconazole for the Treatment of Esophageal Candidiasis in HIV-Positive Patients,” <i>Clin Infect Dis</i>, 2004, 39(6):842-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/15472817/pubmed" id="15472817" target="_blank">15472817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15801925">
<a name="15801925"></a>de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. <i>Aliment Pharmacol Ther.</i> 2005;21(7):899-907. doi:10.1111/j.1365-2036.2005.02427.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/15801925/pubmed" id="15801925" target="_blank">15801925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16678903">
<a name="16678903"></a>Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. <i>J Infect</i>. 2006;53(5):337-349. doi:10.1016/j.jinf.2006.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16678903/pubmed" id="16678903" target="_blank">16678903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21905789">
<a name="21905789"></a>Emiroglu M. Micafungin use in children. <i>Expert Reviews Anti-infective Therapy</i>. 2011;9(9):821-834.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/21905789/pubmed" id="21905789" target="_blank">21905789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746955">
<a name="29746955"></a>Epstein DJ, Seo SK, Huang YT, et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study. <i>J Infect</i>. 2018;77(3):227-234. doi:10.1016/j.jinf.2018.03.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/29746955/pubmed" id="29746955" target="_blank">29746955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.<i> Intensive Care Med.</i> 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fishman.1">
<a name="Fishman.1"></a>Fishman JA, Alexander BD. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93. doi:10.1093/cid/cir073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother</i>. 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21876061">
<a name="21876061"></a>Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. <i>Antimicrob Agents Chemother</i>. 2011;55(11):5107-5112. doi:10.1128/AAC.05193-11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/21876061/pubmed" id="21876061" target="_blank">21876061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24730676">
<a name="24730676"></a>Hashii Y, Kusuki S, Takizawa S, et al. Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection. <i>Pediatr Int</i>. 2014;56(6):834-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/24730676/pubmed" id="24730676" target="_blank">24730676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16172179">
<a name="16172179"></a>Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. <i>J Clin Pharmacol</i>. 2005;45(10):1145-1152. doi:10.1177/0091270005279580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16172179/pubmed" id="16172179" target="_blank">16172179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17133155">
<a name="17133155"></a>Heresi GP, Gerstmann DR, Reed MD, et al. The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants. <i>Pediatr Infect Dis J</i>. 2006;25(12):1110-1115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/17133155/pubmed" id="17133155" target="_blank">17133155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17473532">
<a name="17473532"></a>Hirata K, Aoyama T, Matsumoto Y, et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. <i>Yakugaku Zasshi</i>. 2007;127(5):897-901. doi:10.1248/yakushi.127.897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/17473532/pubmed" id="17473532" target="_blank">17473532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23137136">
<a name="23137136"></a>Hope WW, Castagnola E, Groll AH, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. <i>Clin Microbiol Infect</i>. 2012;18(suppl 7):38-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/23137136/pubmed" id="23137136" target="_blank">23137136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22469884">
<a name="22469884"></a>Huang X, Chen H, Han M, et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. <i>Biol Blood Marrow Transplant</i>. 2012;18(10):1509-1516. doi:10.1016/j.bbmt.2012.03.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/22469884/pubmed" id="22469884" target="_blank">22469884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900296">
<a name="30900296"></a>Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13544. doi:10.1111/ctr.13544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/30900296/pubmed" id="30900296" target="_blank">30900296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.1">
<a name="Kauffman.1"></a>Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 23, 2021c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.2">
<a name="Kauffman.2"></a>Kauffman CA. Oropharyngeal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 17, 2021d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19636279">
<a name="19636279"></a>Kawada M, Fukuoka N, Kondo M, et al. Pharmacokinetics of Prophylactic Micafungin in Very-Low-Birth-Weight Infants. <i>Pediatr Infect Dis J</i>. 2009;28(9):840-842.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19636279/pubmed" id="19636279" target="_blank">19636279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25929612">
<a name="25929612"></a>Kobayashi C, Hanadate T, Niwa T, Yoshiyasu T, So M, Matsui K. Safety and effectiveness of micafungin in Japanese pediatric patients: results of a postmarketing surveillance study. <i>J Pediatr Hematol Oncol</i>. 2015;37(5):e285-e291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/25929612/pubmed" id="25929612" target="_blank">25929612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16915374">
<a name="16915374"></a>Kobayashi S, Murayama S, Tatsuzawa O, et al. X-Linked Severe Combined Immunodeficiency (X-SCID) With High Blood Levels of Immunoglobulins and <i>Aspergillus</i> Pneumonia Successfully Treated With Micafangin Followed by Unrelated Cord Blood Stem Cell Transplantation. <i>Eur J Pediatr</i>. 2007;166(3):207-210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16915374/pubmed" id="16915374" target="_blank">16915374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23743960">
<a name="23743960"></a>Kobayashi R, Suzuki N, Yoshida M, et al. Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: a multicenter prospective study. <i>J Pediatr Hematol Oncol</i>. 2013;35(7):e276-e279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/23743960/pubmed" id="23743960" target="_blank">23743960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15287383">
<a name="15287383"></a>Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. <i>Scand J Infect Dis</i>. 2004;36(5):372-9. doi:10.1080/00365540410020406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/15287383/pubmed" id="15287383" target="_blank">15287383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18983417">
<a name="18983417"></a>Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. <i>Transpl Infect Dis</i>. 2009;11(1):89-93. doi:10.1111/j.1399-3062.2008.00349.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/18983417/pubmed" id="18983417" target="_blank">18983417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29762386">
<a name="29762386"></a>Kovanda LL, Walsh TJ, Benjamin DK Jr, et al. Exposure-response analysis of micafungin in neonatal candidiasis: pooled analysis of two clinical trials. <i>Pediatr Infect Dis J</i>. 2018;37(6):580-585.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/29762386/pubmed" id="29762386" target="_blank">29762386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19533659">
<a name="19533659"></a>Kusuki S, Hashii Y, Yoshida H, et al. Antifungal Prophylaxis With Micafungin in Patients Treated for Childhood Cancer. <i>Pediatr Blood Cancer</i>. 2009;53(4):605-609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19533659/pubmed" id="19533659" target="_blank">19533659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29744900">
<a name="29744900"></a>Leroux S, Jacqz-Aigrain E, Elie V, et al. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. <i>Br J Clin Pharmacol</i>. 2018;84(9):1989-1999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/29744900/pubmed" id="29744900" target="_blank">29744900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25599346">
<a name="25599346"></a>Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. <i>Ann Intern Med</i>. 2015;162(2):81-89. doi:10.7326/M13-2508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/25599346/pubmed" id="25599346" target="_blank">25599346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096213">
<a name="26096213"></a>Maseda E, Grau S, Hernandez-Gancedo C, Suarez-de-la-Rica A, Aguilar L, Gilsanz F. Pharmacokinetics/pharmacodynamics of micafungin in a surgical critically ill patient during extracorporeal carbon dioxide removal and continuous renal replacement therapy. <i>J Crit Care</i>. 2015;30(5):1129-1130. doi:10.1016/j.jcrc.2015.04.117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/26096213/pubmed" id="26096213" target="_blank">26096213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29655372">
<a name="29655372"></a>Maseda E, Grau S, Luque S, et al. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. <i>Crit Care</i>. 2018;22(1):94. doi:10.1186/s13054-018-2019-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/29655372/pubmed" id="29655372" target="_blank">29655372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24505092">
<a name="24505092"></a>Maseda E, Grau S, Villagran MJ, et al. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. <i>J Antimicrob Chemother</i>. 2014;69(6):1624-1632. doi:10.1093/jac/dku013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/24505092/pubmed" id="24505092" target="_blank">24505092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection.<i> Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20546908">
<a name="20546908"></a>Mehta PA, Vinks AA, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. <i>Biol Blood Marrow Transplant</i>. 2010;16(10):1458-1462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/20546908/pubmed" id="20546908" target="_blank">20546908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mycamine.1">
<a name="Mycamine.1"></a>Mycamine (micafungin) [prescribing information]. Leiden, Netherlands: Astellas Pharma Europe B.V.; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mycamine.2">
<a name="Mycamine.2"></a>Mycamine (micafungin) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mycamine.3">
<a name="Mycamine.3"></a>Mycamine (micafungin) [summary of product characteristics]. Leiden, Netherlands: Astellas Pharma Europe B.V.; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi:10.1093/cid/civ933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17806055">
<a name="17806055"></a>Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. <i>Clin Infect Dis</i>. 2007;45(7):883-893. doi:10.1086/520980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/17806055/pubmed" id="17806055" target="_blank">17806055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25670351">
<a name="25670351"></a>Pasipanodya JP, Hall RG 2nd, Gumbo T. In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. <i>Clin Pharmacol Ther</i>. 2015;97(3):292-297. doi:10.1002/cpt.38<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/25670351/pubmed" id="25670351" target="_blank">25670351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patterson.1">
<a name="Patterson.1"></a>Patterson TF. Treatment and prevention of invasive aspergillosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27365388">
<a name="27365388"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/27365388/pubmed" id="27365388" target="_blank">27365388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15298643">
<a name="15298643"></a>Pettengell K, Mynhardt J, Kluyts T, et al. Successful Treatment of Oesophageal Candidiasis by Micafungin: A Novel Systemic Antifungal Agent. <i>Aliment Pharmacol Ther</i>. 2004;20(4):475-481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/15298643/pubmed" id="15298643" target="_blank">15298643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18679151">
<a name="18679151"></a>Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis: Substudy of a Randomized Double-Blind Trial. <i>Pediatr Infect Dis J</i>. 2008;27(9):820-826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/18679151/pubmed" id="18679151" target="_blank">18679151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29601453">
<a name="29601453"></a>Rivera-Chaparro ND, Ericson J, Wu H, et al. Safety, effectiveness and exposure-response of micafungin in infants: application of an established pharmacokinetics model to electronic health records. <i>Pediatr Infect Dis J</i>. 2019;38(2):e26-e28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/29601453/pubmed" id="29601453" target="_blank">29601453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25520332">
<a name="25520332"></a>Saliba F, Pascher A, Cointault O, et al; TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators; TENPIN Liver Transplant European Study Into the Prevention of Fungal Infection Investigators. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. <i>Clin Infect Dis</i>. 2015;60(7):997-1006. doi:10.1093/cid/ciu1128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/25520332/pubmed" id="25520332" target="_blank">25520332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414408">
<a name="17414408"></a>Santos RP, Sánchez PJ, Mejias A, et al. Successful Medical Treatment of Cutaneous <i>Aspergillosis</i> in a Premature Infant Using Liposomal Amphotericin B, Voriconazole and Micafungin. <i>Pediatr Infect Dis J</i>. 2007;26(4):364-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/17414408/pubmed" id="17414408" target="_blank">17414408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24424789">
<a name="24424789"></a>Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatr Blood Cancer</i>. 2014;61(3):393-400. doi:10.1002/pbc.24847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/24424789/pubmed" id="24424789" target="_blank">24424789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16048942">
<a name="16048942"></a>Seibel NL, Schwartz C, Arrieta A, et al. Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients. <i>Antimicrob Agents Chemother</i>. 2005;49(8):3317-3324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16048942/pubmed" id="16048942" target="_blank">16048942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12621247">
<a name="12621247"></a>Singer MS, Seibel NL, Vezina G, et al. Successful Treatment of Invasive <i>Aspergillosis</i> in Two Patients With Acute Myelogenous Leukemia. <i>J Pediatr Hematol Oncol</i>. 2003;25(3):252-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/12621247/pubmed" id="12621247" target="_blank">12621247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19319022">
<a name="19319022"></a>Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. <i>Pediatr Infect Dis J</i>. 2009;28(5):412-415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19319022/pubmed" id="19319022" target="_blank">19319022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26880109">
<a name="26880109"></a>Styczynski J, Czyzewski K, Wysocki M, et al. Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation. <i>Leuk Lymphoma</i>. 2016;57(10):2456-2459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/26880109/pubmed" id="26880109" target="_blank">26880109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23842191">
<a name="23842191"></a>Sun HY, Cacciarelli TV, Singh N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. <i>Transplantation</i>. 2013;96(6):573-578. doi:10.1097/TP.0b013e31829d674f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/23842191/pubmed" id="23842191" target="_blank">23842191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179565">
<a name="30179565"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/30179565/pubmed" id="30179565" target="_blank">30179565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30633087">
<a name="30633087"></a>Tenorio-Cañamás T, Grau S, Luque S, Fortún J, Liaño F, Roberts JA. Pharmacokinetics of micafungin in critically ill patients receiving continuous venovenous hemodialysis with high cutoff membranes. <i>Ther Drug Monit</i>. 2019;41(3):376-382. doi:10.1097/FTD.0000000000000595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/30633087/pubmed" id="30633087" target="_blank">30633087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28317305">
<a name="28317305"></a>Tetsuka N, Yaguchi T, Machida H, Ito S, Miyairi I. Invasive pulmonary aspergillosis due to azole-resistant Aspergillus lentulus. <i>Pediatr Int</i>. 2017;59(3):362-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/28317305/pubmed" id="28317305" target="_blank">28317305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17202726">
<a name="17202726"></a>Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. <i>Intern Med</i>. 2007;46(1):3-9. doi:10.2169/internalmedicine.46.6021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/17202726/pubmed" id="17202726" target="_blank">17202726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated November 21, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf" target="_blank">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.Updated December 9, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15546073">
<a name="15546073"></a>van Burik JA, Ratanatharathorn V, Stepan DE, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. <i>Clin Infect Dis</i>. 2004;39(10):1407-1416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/15546073/pubmed" id="15546073" target="_blank">15546073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vazquez.1">
<a name="Vazquez.1"></a>Vazquez JA. Candida osteoarticular infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vazquez.2">
<a name="Vazquez.2"></a>Vazquez JA. Management of candidemia and invasive candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25551699">
<a name="25551699"></a>Viscoli C, Bassetti M, Castagnola E, et al. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. <i>BMC Infect Dis</i>. 2014;14:725.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/25551699/pubmed" id="25551699" target="_blank">25551699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28584142">
<a name="28584142"></a>Vossen MG, Knafl D, Haidinger M, et al. Micafungin plasma levels are not affected by continuous renal replacement therapy: experience in critically ill patients. <i>Antimicrob Agents Chemother</i>. 2017;61(8):e02425-16. doi:10.1128/AAC.02425-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/28584142/pubmed" id="28584142" target="_blank">28584142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30649375">
<a name="30649375"></a>Wasmann RE, Smit C, Ter Heine R, et al. Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. <i>J Antimicrob Chemother</i>. 2019;74(4):978-985. doi:10.1093/jac/dky554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/30649375/pubmed" id="30649375" target="_blank">30649375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.1">
<a name="Wingard.1"></a>Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26602452">
<a name="26602452"></a>Xu G, Zhu L, Liao S, Ge T, Yang J. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients. <i>Int J Antimicrob Agents</i>. 2015;46(6):631-641.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/26602452/pubmed" id="26602452" target="_blank">26602452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16595990">
<a name="16595990"></a>Yanada M, Kiyoi H, Murata M, et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. <i>Intern Med</i>. 2006;45(5):259-264. doi:10.2169/internalmedicine.45.1498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16595990/pubmed" id="16595990" target="_blank">16595990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21449041">
<a name="21449041"></a>Yanni, SB, Smith PB, Benjamin DK, et al. Higher clearance of micafungin in neonates compared to adults: rose of age-dependent micafungin serum binding. <i>Biopharm Drug Dispos</i>. 2011;32(4):222-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/21449041/pubmed" id="21449041" target="_blank">21449041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14661114">
<a name="14661114"></a>Yokote T, Akioka T, Oka S, et al. Successful Treatment With Micafungin of Invasive Pulmonary Aspergillosis in Acute Myeloid Leukemia, With Renal Failure Due to Amphotericin B Therapy. <i>Ann Hematol</i>. 2004;83(1):64-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/14661114/pubmed" id="14661114" target="_blank">14661114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24567233">
<a name="24567233"></a>Yoshikawa K, Nakazawa Y, Katsuyama Y, et al. Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Infection</i>. 2014;42(4):639-647.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/24567233/pubmed" id="24567233" target="_blank">24567233</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12713 Version 290.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
